Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 392 entries.
Entries by Thomas Gabrielczyk
NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.
Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
French Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.